Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. The participant has been diagnosed with uterine fibroids and has never received surgical treatment for the myoma.~2. The participant is a premenopausal woman.~3. The participant has one or more measurable noncalcified myomas confirmed by transvaginal sonography.~4. The participant has experienced regular menstrual cycles~5. The participant is diagnosed as menorrhagia~Exclusion Criteria:~1. Participants with a screening Hb \<8 g/dL~2. Participants with a previous or current history of blood disorders~3. Participants with a known history of severe hypersensitivity or severe allergy to sanitary goods~4. Participants with lower abdominal pain due to irritable bowel syndrome or severe interstitial cystitis~5. Participants with a previous or current history of thyroid dysfunction~6. Participants with a previous or current history of pelvic inflammatory disease~7. Participants with a positive PAP smear test result~8. Participants with a history of panhysterectomy or bilateral oophorectomy~9. Participants judged by investigator to have marked abnormal uterine bleeding or anovulatory bleeding~10. Participants with a previous or current history of a malignant tumor~11. Participants who have been treated with any of the following drugs: anticoagulant drug, antiplatelet drug, tranexamic acid, selective estrogen receptor modulator (SERM), activated vitamin D, other vitamin D, calcitonin, ipriflavone, steroid hormone, vitamin K, teriparatide, or denosumab~12. Participants who have been treated with any of the following drugs: oral contraceptive and sex hormone preparation, gonadotropin-releasing hormone (GnRH) analogue, dienogest, danazol, or aromatase inhibitor~13. Participants who have been treated with a bisphosphonate preparation~14. Participants with a previous or current history of severe hypersensitivity or severe allergy to drugs~15. Participants with non-diagnosable abnormal genital bleeding~16. Participants with a previous or current history of osteoporosis, bone mass loss, or other metabolic bone diseases~17. Participants with clinically significant cardiovascular disease or uncontrollable hypertension~18. Participants judged by investigator to be inappropriate to participate in this study based on the 12-lead electrocardiogram (ECG) findings~19. Participants with active liver disease or jaundice, or with alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin \> 1.5 times the upper limit of normal (ULN)

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAK-385 10 mg QD (Type: EXPERIMENTAL): None
- TAK-385 20 mg QD (Type: EXPERIMENTAL): None
- TAK-385 40 mg QD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).